Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

BACKGROUND: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with chemotherapy. In this study, we investigated the role of complement activation in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Yi-Fan, Ajona, Daniel, Corrales, Leticia, Lopez-Picazo, Jose M, Gurpide, Alfonso, Montuenga, Luis M, Pio, Ruben
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893457/
https://www.ncbi.nlm.nih.gov/pubmed/20529262
http://dx.doi.org/10.1186/1476-4598-9-139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893457/
https://www.ncbi.nlm.nih.gov/pubmed/20529262
http://dx.doi.org/10.1186/1476-4598-9-139

Ejemplares similares